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A B S T R A C T
Purpose: To evaluate the prognostic importance of electroencephalography (EEG) ﬁndings at cessation of
epileptic spasms for seizure outcome.
Methods: We reviewed 71 children with West syndrome (cryptogenic 14) who had obtained control of
epileptic spasms with initial treatment (adrenocorticotropic hormone (ACTH) 37, high-dose vitamin B6
2, and antiepileptic drugs 32). According to the EEG ﬁndings at control of epileptic spasms, the subjects
were divided into three groups: normal group (no epileptic activity, n = 12), abnormal group (residual
epileptic activity without hypsarrhythmia, n = 53), and hypsarrhythmic group (persisting hypsar-
rhythmia, n = 6).
Results: Overall, 47 (66%) of the 71 patients (cryptogenic 4) had experienced relapses of seizures
(epileptic spasms 23 and focal seizure 24) after initial control of epileptic spasms. Within symptomatic
cases, seizure relapse rate varied widely from 0% (Down syndrome) to 100% (tuberous sclerosis),
depending on underlying causes. Seizure relapse depended on the EEG ﬁndings at control of epileptic
spasms. The normal group had a signiﬁcantly lower seizure relapse rate (17%) in comparison with the
abnormal group (75%), the hypsarrhythmic group (83%), and the epileptiform (abnormal plus
hypsarrhythmic, 76%) group. No signiﬁcant difference in seizure relapse rate was observed between
non-hypsarrhythmic (normal plus abnormal, 65%) and hypsarrhythmic groups. At the last follow-up,
normal group children also showed a favorable seizure prognosis (seizure control 100%).
Conclusions: A favorable seizure prognosis is associated with the disappearance of epileptic activity, but
not the resolution of hypsarrhythmic pattern on EEG at control of epileptic spasms. We suggest that
effective treatment for West syndrome should produce both cessation of epileptic spasms and
disappearance of epileptic activity on EEG.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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West syndrome is an age-related epileptic encephalopathy of
infancy characterized by ﬂexor/extensor type of epileptic spasms
that usually occur in clusters, hypsarrhythmia on electroencepha-
lography (EEG), and developmental arrest or regression. From
evidence-based practice guidelines with a full literature review, it
was concluded that adrenocorticotropic hormone (ACTH) and
vigabatrin are the only drugs with proven efﬁcacy for the ﬁrst-line
treatment of West syndrome.1,2 However, long-term studies
revealed that a substantial number of responders to either ACTH* Corresponding author at: Department of Pediatric Neurology, Osaka Medical
Center and Research Institute for Maternal and Child Health, 840 Murodo-cho,
Izumi, Osaka 594-1101, Japan. Tel.: +81 725 56 1220; fax: +81 725 56 5682.
E-mail address: keitaro_ymd1976@yahoo.co.jp (K. Yamada).
http://dx.doi.org/10.1016/j.seizure.2014.05.010
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reor vigabatrin had experienced relapse of epileptic spasms or
development of other seizures.1
Previous studies have reported on both patient and treatment
variables that seem to be implicated in the neurodevelopmental
and seizure prognosis. Although these studies yielded conﬂicting
results,3–11 there is general agreement that outcomes are most
dependent on underlying disorders and may be more favorable in
cryptogenic etiology. Early recognition and prompt treatment may
improve outcomes in some patients, particularly in those with
cryptogenic West syndrome.2,6 Other possible prognostic indica-
tors associated with a favorable prognosis include normal
development prior to the onset of epileptic spasms, normal
imaging study results, absence of other seizure types, and
sustained response to therapy without relapse.12
Most pediatric neurologists believe that effective treatment for
West syndrome should produce both cessation of epileptic spasms
and resolution of hypsarrhythmia on EEG. However, the prognosticserved.
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been evaluated formally. To evaluate the predictive value of EEG
ﬁndings at control of epileptic spasms for seizure outcome, we
reviewed patients with newly diagnosed West syndrome who had
cessation of epileptic spasms with initial treatment.
2. Materials and methods
We retrospectively reviewed the medical records of 164
patients (cryptogenic 28 and symptomatic 136) with newly
diagnosed West syndrome who received initial treatment (deﬁned
as the ﬁrst ﬁve therapeutic regimens) at Osaka Medical Center and
Research Institute for Maternal and Child Health, Osaka, Japan,
between 1982 and 2008. In our institute, the drug selection was
basically based on the treating physician’s decision. The most
commonly used drug as the initial treatment was high-dose
vitamin B6, followed by zonisamide, sodium valproate, and ACTH.
Our ACTH treatment protocol was as follows. Before 2000,
synthetic ACTH was given intramuscularly at 0.025 mg/kg per
day for 2 weeks, then gradually tapered off to once every other day
for 2 weeks, twice weekly for 2 weeks, and then once a week for 2
weeks (daily ACTH treatment). Thereafter, shortened ACTH
treatment was introduced13; ACTH (0.025 mg/kg) was adminis-
tered seven times on every other day for 2 weeks. Only patients
with persistent epileptic spasms received additional therapy for 1
or 2 weeks with the same daily dose of ACTH, which was tapered
off over a few weeks. If treatment with one drug failed to control
epileptic spasms completely at the time of the last dose (ACTH), or
at the maximal dose (vitamin B6 or antiepileptic drug), it was
replaced by another treatment. Response to therapy was deﬁned as
total cessation of clinically deﬁned epileptic spasms by parental
and/or nursing observation for over 28 days.
In the initial treatment, 48 infants (cryptogenic 2 and
symptomatic 46) failed to respond to the ﬁrst- to ﬁfth-choice
therapeutic regimens. The remaining 116 patients (cryptogenic 26
and symptomatic 90) had achieved control of epileptic spasms for
over 28 days with initial treatment. Of these 116 responders, the
subjects of this study included 71 patients (cryptogenic 14 and
symptomatic 57) who were followed regularly for at least three
years after the cessation of epileptic spasms with initial treatment
(8 ﬁrst-choice drug responders, 14 second-choice drug responders,
24 third-choice drug responders, 13 fourth-choice drug respond-
ers, and 12 ﬁfth-choice drug responders).
In all patients, prolonged video EEGs, including full wake and
sleep cycle, were recorded before the ﬁrst-choice drug was
allocated, and within two weeks after cessation of epileptic
spasms. Routine EEGs were performed during the initial treatment.
All were well-documented cases with typical clinical epileptic
spasms, and EEG changes of hypsarrhythmia or modiﬁed hypsar-
rhythmia at the active stage of clinically deﬁned epileptic spasms.
Hypsarrhythmia was characterized by chaotic, non-rhythmic,
asynchronous, disorganized, high-voltage spike and slow-wave
activity.12 Modiﬁed hypsarrhythmia was deﬁned according to
Hrachovy et al.14 The EEGs were re-evaluated by one pediatric
neurologist blinded to the clinical presentation. We compared his
assessment with previous EEG reports. Differences were resolved
using judgment by another pediatric neurologist. On the basis of
the EEG ﬁndings at control of epileptic spasms, the subjects were
divided into three groups: normal group (no epileptic activity with
or without normal background EEG), abnormal group (residual
epileptic activity without hypsarrhythmia), and hypsarrhythmic
group (persisting hypsarrhythmia or modiﬁed hypsarrhythmia).
We compared the clinical (age at onset, sex, classiﬁcation, and
etiology) and initial treatment parameters (treatment lag, effective
drug, number of drugs used before cessation of epileptic spasms,
and time to response from onset) among the three groups. Time toresponse from onset is deﬁned as the time from onset of epileptic
spasms to their cessation. Seizure outcome (seizure relapse and
seizure control at last follow-up) and EEG ﬁndings at last follow-up
were also compared. In this study, seizure relapse was deﬁned as
development of any type of seizure after initial control of epileptic
spasms, including both relapse of epileptic spasms and progression
to other epilepsy. Children were considered cryptogenic if they
fulﬁlled the following criteria: (a) no known associated etiology,
(b) normal development and neurologic examination before onset
of epileptic spasms, (c) no previous seizure, and (d) normal brain
imaging. The symptomatic cases were further classiﬁed into three
etiologic subgroups depending on the timing of presumed causes:
prenatal, perinatal, and postnatal subgroups.
Statistical studies were performed using Kruskal–Wallis test to
compare clinical and initial treatment parameters among the three
groups. Mann–Whitney U test and Fisher’s exact probability test
were used for comparisons between two groups. Chi-square test
was used for comparison among the ﬁrst- to ﬁfth-choice drug
responder groups. A difference was considered signiﬁcant with a p
value of 0.05 or less.
3. Results
The patients’ clinical proﬁles are summarized in Table 1. There
were 12 children in the normal group, 53 in the abnormal group,
and six in the hypsarrhythmic group. We found no signiﬁcant
differences in gender distribution and age at onset among the three
groups. In the normal group, seven infants were classiﬁed as
cryptogenic and ﬁve as symptomatic. In contrast, both abnormal
and hypsarrhythmic groups showed a predominance of symptom-
atic cases. There were also no signiﬁcant differences in treatment
lag and the number of drugs used before cessation of epileptic
spasms among the three groups. The mean time to response from
onset did not differ among the three groups, and the median values
were similar among the groups (normal group, 2.0 months;
abnormal group, 2.0 months; hypsarrhythmic group, 1.9 months).
Thirty-seven patients (ACTH responders) had cessation of epileptic
spasms after ACTH treatment (daily ACTH treatment 23, and
shortened ACTH treatment 14). Of the remaining 34 infants (non-
ACTH responders), including three who had failed to respond to
ACTH (daily ACTH treatment 2, and shortened ACTH treatment 1),
two infants had remission of epileptic spasms with high-dose
vitamin B6 therapy and 32 responded to antiepileptic drugs. ACTH
responders accounted for half or more of the patients in the normal
(6/12) and abnormal groups (30/53), while there was only one
ACTH responder in the hypsarrhythmic group (1/6). Effective
antiepileptic drugs were similar in the three groups.
Seizure outcomes are shown in Table 2. There were no
signiﬁcant differences in age at last follow-up among the three
groups. Overall, 47 (66%) of the 71 patients had experienced
relapses of seizures during the course of illness. Regarding types of
recurrent seizure, none had generalized seizures. Epileptic spasms
recurred in 23 patients, and focal seizures developed in 24 patients.
We found no signiﬁcant (p = 0.44) difference in seizure relapse rate
among the ﬁve (ﬁrst- to ﬁfth-choice drug) responder groups (ﬁrst-
choice drug responders 6/8, second-choice drug responders 8/14,
third-choice drug responders 17/24, fourth-choice drug respond-
ers 9/13, and ﬁfth-choice drug responders 7/12). The mean time
from initial control of epileptic spasms to seizure relapse was
signiﬁcantly shorter (p = 0.0003) in patients who showed relapse
of epileptic spasms (mean, 7.0 months; range, 1.5–24 months)
than in those who developed focal seizure (mean, 51.8 months;
range, 1.5–173 months) (Fig. 1). Symptomatic patients showed a
higher relapse rate (75%) than cryptogenic patients (29%) (Table 2).
Etiology and seizure relapse rate in patients with symptomatic












Age at last follow-up (years)
Mean  SD 12.0  5.7 9.7  5.6 12.6  5.8 11.9  4.8 0.29
(Range) (3.5–27.7) (3.7–20.8) (3.5–27.7) (4.7–17.3)
Seizure relapse, no. (%)
Overall 47 (66%) 2 (17%)*,** 40 (75%) 5 (83%) 0.0003
Cryptogenic 4 (29%) 1 (14%) 2 (33%) 1 (100%) 0.15
Symptomatic 43 (75%) 1 (20%)* 38 (81%) 4 (80%) 0.03
Seizure type at relapse, no.
Epileptic spasms 23 1 21 1
Focal seizure 24 1 19 4 –
Generalized seizure 0 0 0 0
Seizure control at last follow-up, no. (%) 44 (62%) 12 (100%)*,** 29 (55%) 3 (50%) 0.008
EEG normalization at last follow-up, no. (%) 19 (27%) 11 (92%)*,** 9 (17%) 0 (0%) <0.0001
* Signiﬁcantly different from abnormal group (p < 0.05).












Sex (male/female) 45/26 8/4 33/20 4/2 0.94
Age at onset (mean  SD, months) 6.9  3.4 6.6  2.6 6.9  3.5 7.7  4.2 0.90
Classiﬁcation
Cryptogenic 14 7* 6 1 0.001
Symptomatic 57 5* 47 5
Prenatal 26 2 21 3
Perinatal 25 3 21 1
Postnatal 6 0 5 1
Treatment lag (mean  SD, weeks) 4.9  5.3 4.9  4.3 4.8  5.6 6.0  5.0 0.60
Time to response from onset (months)
Mean  SD 3.2  3.9 3.3  3.7 3.2  4.0 2.8  3.0 0.83
Median (range) 2.0 (0.3–21.3) 2.0 (0.75–14) 2.0 (0.3–21.3) 1.9 (1.0–9.0)
No. of drugs used before cessation of
epileptic spasms (mean  SD)
3.1  1.2 3.2  1.1 3.2  1.1 2.2  1.6 0.18
Effective drug
ACTH 37 6 30 1 0.23
B6 2 0 1 1
AEDs 32 6 22 4
(VPA 3, ZNS 2, NZP 1) (VPA 8, ZNS 7, CZP 4,
NZP 1, AZA 1, PHT 1)
(VPA 2, ZNS 2)
ACTH = adrenocorticotropic hormone; B6 = high-dose vitamin B6; AEDs = antiepileptic drugs; VPA = sodium valproate; ZNS = zonisamide; NZP = nitrazepam; AZA = acetazo-
lamide; CZP = clonazepam; PHT = phenytoin.
* Signiﬁcantly different from abnormal group (p < 0.05).
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while there was no postnatal subgroup in the normal group.
Seizure relapse rate may vary depending on etiologic subgroups or
underlying disorders. All six cases of postnatal origin (infantileFig. 1. Overall, 47 (66%) of the 71 patients had experienced relapses of seizures
(epileptic spasms 23, focal seizure 24) after initial cessation of epileptic spasms. The
mean time from initial control of epileptic spasms to seizure relapse was
signiﬁcantly shorter (p = 0.0003) in patients (upper) who showed relapse of
epileptic spasms (mean, 7.0 months; range, 1.5–24 months) than in those (lower)
who developed focal seizure (mean, 51.8 months; range, 1.5–173 months).
Hyps = hypsarrhythmia.intracranial hemorrhage and encephalopathy) had relapsed.
Seizures recurred in all seven children with tuberous sclerosis,
and in all four with brain anomaly. In contrast, none of four
patients with Down syndrome had seizure relapses regardless of
EEG ﬁndings.
A marked difference (p = 0.0003) was observed in seizure
relapse rate among the groups (Table 2): only two (17%) of 12
normal-group children had seizure relapse, while 40 (75%) of 53
abnormal-group patients and ﬁve (83%) of six in the hypsar-
rhythmic group had relapsed after initial control of epileptic
spasms. The differences reached statistical signiﬁcance between
normal and abnormal groups (p = 0.0003), and between normal
and hypsarrhythmic groups (p = 0.0062). To focus on the disap-
pearance of epileptic paroxysm, we then combined the data of the
abnormal and hypsarrhythmic groups as an epileptiform group.
The normal group (2/12) had a signiﬁcantly (p = 0.0002) lower
seizure relapse rate than the epileptiform group (45/59) (Fig. 2,
left). In a separate analysis of cryptogenic and symptomatic cases,
this low relapse rate of the normal group was conﬁrmed in the
symptomatic subgroup (normal group 1/5 vs. epileptiform group
42/52, p = 0.01). In the cryptogenic subgroup, the normal group (1/
7) showed a lower seizure relapse rate than the epileptiform group
(3/7), but the difference did not reach signiﬁcance (p = 0.17).
Table 3
Etiology and seizure relapse rate in patients with symptomatic West syndrome.
Etiology Total Normal group Abnormal group Hypsarrhythmic group
Relapse rate (relapse cases/total cases) 75% (43/57) 20% (1/5) 81% (38/47) 80% (4/5)
Prenatal
Down syndrome 0% (0/4) 0% (0/1) 0% (0/2) 0% (0/1)
Microcephalus 0% (0/1) – 0% (0/1) –
NF-1 100% (1/1) – 100% (1/1) –
Tuberous sclerosis 100% (7/7) 100% (1/1) 100% (5/5) 100% (1/1)
Brain anomaly 100% (4/4) – 100% (4/4) –
NKH 100% (1/1) – – 100% (1/1)
Congenital CMV infection 100% (1/1) – 100% (1/1) –
Unknown 86% (6/7) – 86% (6/7) –
Perinatal
HIE 67% (8/12) 0% (0/1) 73% (8/11) –
LBWI 33% (1/3) 0% (0/1) 50% (1/2) –
ICH 67% (4/6) 0% (0/1) 75% (3/4) 100% (1/1)
PVL 100% (2/2) – 100% (2/2) –
Infarction 100% (2/2) – 100% (2/2) –
Postnatal
Infantile ICH 100% (3/3) – 100% (3/3) –
Encephalopathy 100% (3/3) – 100% (2/2) 100% (1/1)
NF-1 = neuroﬁbromatosis type 1; NKH = non-ketotic hyperglycinemia; CMV = cytomegalovirus; HIE = hypoxic–ischemic encephalopathy; LBWI = low-birth-weight infant;
ICH = intracranial hemorrhage; PVL = periventricular leukomalacia.
K. Yamada et al. / Seizure 23 (2014) 703–707706Although convincing evidence is lacking, most pediatric neurol-
ogists believe that effective treatment for West syndrome should
produce both cessation of epileptic spasms and resolution of
hypsarrhythmia on EEG. Therefore, we combined the data of
normal and abnormal groups as a non-hypsarrhythmic group with
a focus on the resolution of hypsarrhythmia. However, we found no
signiﬁcant difference (p = 0.58) in seizure relapse rate between
non-hypsarrhythmic (42/65) and hypsarrhythmic groups (5/6)
(Fig. 2, right).
At the last follow-up, there were signiﬁcant differences in seizure
control (p = 0.008) and EEG normalization (p < 0.0001) among the
three groups (Table 2). All normal group patients (12/12) achieved
seizure control, in contrast to the abnormal group (29/53) and the
hypsarrhythmic group (3/6). EEG normalization was observed in 11
(92%) of 12 cases in the normal group, and in nine (17%) of 53 in the
abnormal group. In contrast, none of the hypsarrhythmic group
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Fig. 2. In this study, 47 (66%) of 71 children with West syndrome who had obtained
control of epileptic spasms (>28 days) with initial treatment had experienced
relapses of seizures (epileptic spasms 23 and focal seizure 24). According to the EEG
ﬁndings at control of epileptic spasms, the subjects were divided into three groups:
normal group (no epileptic activity, n = 12), abnormal group (residual epileptic
activity without hypsarrhythmia, n = 53), and hypsarrhythmic group (persisting
hypsarrhythmia, n = 6). To focus on the disappearance of epileptic paroxysm, we
combined the data of the abnormal and hypsarrhythmic groups as an epileptiform
group. The normal group (2/12) had a signiﬁcantly (p = 0.0002) lower seizure
relapse rate than the epileptiform group (45/59) (left). When the data of normal and
abnormal groups were combined as a non-hypsarrhythmic group with a focus on
the resolution of hypsarrhythmia, however, no signiﬁcant difference (p = 0.58) in
seizure relapse rate was observed between non-hypsarrhythmic (42/65) and
hypsarrhythmic groups (5/6) (right). Hyps= hypsarrhythmia.reached signiﬁcance between normal and abnormal groups (seizure
control: p = 0.0027, EEG normalization: p < 0.0001), and between
normal and hypsarrhythmic groups (seizure control: p = 0.02, EEG
normalization: p = 0.0004).
4. Discussion
Since the introduction of ACTH in 1958,15 vigabatrin represents
the only antiepileptic drug with proven efﬁcacy for ﬁrst-line
treatment of West syndrome.1 In Japan, however, vigabatrin has
not yet been approved for use. A Japanese survey performed in
2005 revealed that pediatric neurologists used high-dose vitamin
B6 most frequently as the ﬁrst-choice drug, followed by sodium
valproate, zonisamide, and ACTH.16 However, current Japanese
guidelines for the treatment of West syndrome recommend that
ACTH should be introduced within one month after onset,
especially in patients with non-symptomatic West syndrome.17
In our institute, the drug selection was basically based on the
treating physician’s decision. The most commonly used ﬁrst-
choice drug was high-dose vitamin B6 before 1994. After 1995,
zonisamide, which has been marketed since 1989, was also used as
the ﬁrst-choice drug. In this study, we reviewed the effectiveness
of the drugs administered to 164 patients with newly diagnosed
West syndrome between 1982 and 2008. Seventy-one percent
(116/164) of the patients responded to the ﬁrst- to ﬁfth-choice
drugs used as the initial treatment. This result suggests that the
therapeutic regimens available in Japan had limited effectiveness
in the initial treatment of West syndrome.
The West Delphi Group proposed two appropriate primary
outcomes in the treatment of West syndrome: primary clinical
outcome (deﬁned as complete cessation of epileptic spasms) and
primary electroclinical outcome (deﬁned as complete cessation of
epileptic spasms with resolution of hypsarrhythmia on EEG).18 In
retrospective ACTH short-term studies, the response rates for
cessation of epileptic spasms (primary clinical outcome) ranged
from 59% to 100%, and resolution of hypsarrhythmia from 57% to
97%.1 However, little is known about how often the clinical response
is associated with resolution of hypsarrhythmia.18 In this study, 65
(92%) of the 71 subjects showed resolution of hypsarrhythmia,
indicating that 92% of primary clinical responders were regarded as
primary electroclinical responders in our study population. Of note,
the majority of patients without resolution of hypsarrhythmia were
non-ACTH (high-dose vitamin B6, zonisamide, and sodiumvalproate)
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effect on the EEG, in comparison with ACTH.
Most previous studies revealed that approximately 20–50% of
patients who responded to ACTH had experienced relapse of
seizures, but some researchers have documented rates as high as
62%.1 The reported relapse rate after vigabatrin treatment ranged
from 0% to 63%, depending on the study design and the follow-up
period.1,8,19,20 There are insufﬁcient data on the relapse rates after
treatment with other therapeutic regimens. In this study, 47 (66%)
of 71 initial treatment responders had experienced seizure
relapses (epileptic spasms in 23 children and focal seizures in
24). Symptomatic patients showed a higher relapse rate (75%) than
cryptogenic patients (29%). Although the small number of patients
is a limitation of this study, seizure relapse rate may vary widely
depending on underlying causes within symptomatic cases: the
relapse rate is high in some etiologies such as tuberous sclerosis
(100%), in contrast to a low relapse rate in children with Down
syndrome (0%). Further studies with more symptomatic patients
are needed to conﬁrm our results.
This is the ﬁrst study in which the prognostic importance of EEG
ﬁndings at control of epileptic spasms was evaluated in patients
with West syndrome. Seizure relapse after initial treatment
depended on EEG ﬁndings at control of epileptic spasms. Patients
with no epileptic activity (normal group) had a signiﬁcantly lower
seizure relapse rate (17%), in comparison with children with
residual epileptic activity without hypsarrhythmia (abnormal
group, 75%), and those with persisting hypsarrhythmia (hypsar-
rhythmic group, 83%). We then combined the data with a focus on
the disappearance of epileptic paroxysm or hypsarrhythmia. A
signiﬁcant difference in seizure relapse rate was observed between
normal and epileptiform (abnormal plus hypsarrhythmic, 76%)
groups, but not between non-hypsarrhythmic (normal plus
abnormal, 65%) and hypsarrhythmic groups. In a further separate
analysis of cryptogenic and symptomatic cases, we found a lower
seizure relapse rate tendency in the normal group than in the
epileptiform group, in each subgroup. These results showed that
mere resolution of hypsarrhythmia at control of spasms did not
decrease the risk of seizure relapse. Disappearance of epileptic
activity may be associated with a sustained response without
relapse after initial treatment. Furthermore, normal-group chil-
dren had a favorable prognosis (seizure control 100% and EEG
normalization 92%) at the last follow-up relative to the other two
groups.
In conclusion, our study revealed that a favorable seizure
prognosis is associated with the disappearance of epileptic activity
on EEG at control of epileptic spasms. In addition to the cessation of
epileptic spasms, effective treatment for West syndrome should be
targeted to produce abolition of epileptic activity and resolution of
hypsarrhythmic pattern. With currently available agents, however,
we cannot expect epileptic activity to disappear even if the
hypsarrhythmic pattern has resolved. New treatment options
may be needed for improvement of seizure prognosis in patients
with West syndrome. These options include development of a novel
antiepileptic drug with a stronger effect on the EEG or individualizedACTH treatment protocol, in which the duration of ACTH treatment
is extended or the dose of ACTH is increased, depending on EEG
ﬁndings, for patients who respond clinically to ACTH treatment, but
show no abolition of epileptic activity on EEG.
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